547 results on '"Poch, Michael"'
Search Results
52. Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs
53. Using Percentage of Sarcomatoid Differentiation as a Prognostic Factor in Renal Cell Carcinoma
54. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension
55. Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials
56. Clinical Evaluation and Treatment of Male Factor Infertility
57. Surgical Outcomes in the Management of Isolated Nodal Recurrences: A Multicenter, International Retrospective Cohort
58. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection
59. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy ± intensity modulated radiation therapy
60. Urethral Stricture and Urethroplasty in the Pelvic Irradiated Patient
61. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
62. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy
63. 191 Targeting myeloid-derived suppressor cells (MDSCs) in bladder cancer to enhance efficacy of adoptive cell therapy (ACT)
64. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center
65. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection
66. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease
67. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome
68. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study
69. Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer
70. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease
71. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
72. Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).
73. Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma.
74. MP40-04 PREDICTIVE RISK FACTORS FOR EARLY RECURRENCE AFTER RADICAL NEPHROURETERECTOMY FOR LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA
75. MP54-04 A PHASE II STUDY OF CHECK POINT INHIBITOR, DURVALUMAB (MEDI4736) FOR BACILLUS CALMETTE-GUERIN UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER
76. PD58-02 NOVEL USE OF CTDNA TO IDENTIFY LOCALLY ADVANCED AND METASTATIC UPPER TRACT UROTHELIAL CARCINOMA
77. MP56-16 SURGICAL MANAGEMENT OF CLINICALLY LOCALIZED URACHAL CARCINOMA: EVALUATING THE ROLE OF LYMPHADENECTOMY AS STANDARD OF CARE
78. MP03-16 FEASIBILITY, USABILITY AND UTILITY OF A REMOTE SYMPTOM ASSESSMENT TOOL AFTER RADICAL CYSTECTOMY
79. IS PERCENT SEMINOMA ASSOCIATED WITH INTRAOPERATIVE MORBIDITY DURING POST-CHEMOTHERAPY RPLND?: PD34-02
80. ENHANCED RECOVERY AFTER SURGERY AND RADICAL CYSTECTOMY: BENEFITS OF A MULTIDISCIPLINARY APPROACH: MP63-13
81. CLINICAL ROLE OF ADDITIONAL ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED UROTHELIAL CARCINOMA FOLLOWING NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY: MP49-15
82. NEXT: A single-arm, phase 2, open-label study of adjuvant nivolumab after completion of chemo-radiation therapy in patients with localized muscle-invasive bladder cancer.
83. Novel use of ctDNA to identify locally advanced and metastatic upper tract urothelial carcinoma.
84. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort
85. PD41-01 TISSUE IS THE ISSUE: THE IMPACT AND BENEFIT OF PATHOLOGICAL REVIEW FOR UROTHELIAL CARCINOMA OF THE BLADDER AT A TERTIARY CARE CANCER CENTER
86. MP59-10 SARCOPENIA AS A PREDICTOR OF SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA
87. MP59-20 SURGICAL RESECTION OF ISOLATED RETROPERITONEAL LYMPH NODE RECURRENCE OF RCC: RESULTS FROM A MULTI-INSTITUTIONAL INTERNATIONAL COHORT
88. MP50-02 IS FOLLOW UP BEYOND 2 YEARS NECESSARY FOR PT1A RENAL CELL CARCINOMA TREATED WITH NEPHRON SPARING SURGERY? AN ASSESSMENT OF LATE RECURRENCES AND SURVEILLANCE COSTS.
89. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study.
90. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
91. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer
92. Status of Robot-Assisted Radical Cystectomy (RARC) in 2012
93. THE IMPACT OF TUMOR SIZE ON RECURRENCE−FREE SURVIVAL FOR UPPER TRACT UROTHELIAL CARCINOMA.: PD35-01
94. COMPARISON OF ONCOLOGIC OUTCOMES FOLLOWING SYSTEMIC NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY IN PATIENTS WITH MIXED HISTOLOGIC VARIANTS AND PURE UROTHELIAL CARCINOMA OF THE BLADDER: MP61-04
95. BODY-MASS INDEX IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: PD18-12
96. COMPLICATIONS OF RADICAL CYSTECTOMY IN THE NEOADJUVANT CHEMOTHERAPY ERA: MP50-18
97. CHRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER: TRENDS IN CHEMOTHERAPY USAGE AND EFFECTS ON SURVIVAL: MP50-19
98. A NOVEL METHOD OF STRATIFICATION OF COMPLICATION OF RADICAL CYSTECTOMY USING THE COMPREHENSIVE COMPLICATION INDEX: MP50-04
99. UTILIZING PERCENTAGE OF SARCOMATOID DIFFERENTIATION AS A PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA: MP30-20
100. PD09-02 ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.